There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IQVIA Holdings (IQV – Research Report) and Denali Therapeutics (DNLI – Research Report) with bullish sentiments.
IQVIA Holdings (IQV)
BTIG analyst David Larsen maintained a Buy rating on IQVIA Holdings today and set a price target of $290.00. The company’s shares closed last Friday at $238.60, close to its 52-week high of $243.82.
According to TipRanks.com, Larsen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $265.75, implying a 10.1% upside from current levels. In a report issued on February 14, Bank of America Securities also maintained a Buy rating on the stock with a $255.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Denali Therapeutics (DNLI)
BTIG analyst Thomas Shrader maintained a Buy rating on Denali Therapeutics today and set a price target of $35.00. The company’s shares closed last Friday at $17.02, close to its 52-week low of $15.45.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of
Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $48.83, a 174.6% upside from current levels. In a report issued on February 9, Oppenheimer also maintained a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IQV:
